Sign in Create account

Lotus Eye Hospital and Institute Limited

Healthcare · Healthcare Services

NSE: LOTUSEYE BSE: 532998
₹115.89
▲ 2.69 (2.38%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
39/100
Weak
Valuation
20/100
Expensive
Momentum
68/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹241 Cr
PE (TTM)
1448.6
Industry median 50.2 (44 companies)
Price to Book
4.0
PEG (TTM)
-19.3
Institutions holding %
Data unavailable.
Piotroski Score
5
Relative return vs Nifty50, qtr %
3.5
Relative return vs Sector, qtr %
0.6
Free Cash Flow
₹-10 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
15.38%
as of June 30, 2026
Industry median 13.27% (57 companies)
Net Profit Growth (TTM)
0.00%
as of June 30, 2026
Industry median 7.21% (57 companies)
Operating Revenue Growth (TTM)
14.08%
as of June 30, 2026
Industry median 12.82% (57 companies)
Profit Growth (YoY)
-12.52%
as of June 30, 2025
Industry median 8.53% (57 companies)
Revenue Growth (YoY)
26.19%
as of June 30, 2026
Industry median 18.84% (52 companies)
Current Ratio
1.22
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
0.19
as of March 31, 2026
Industry median 0.11 (62 companies)
Interest Coverage
1.18
as of June 30, 2026
Industry median 7.94 (57 companies)
Net Margin
4.03%
as of June 30, 2025
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
8.89%
as of June 30, 2026
Industry median 17.21% (61 companies)
Operating Margin (TTM)
2.58%
as of June 30, 2026
Industry median 16.20% (59 companies)
Return on Assets
0.80%
as of March 31, 2026
Industry median 5.40% (58 companies)
Return on Capital Employed
1.10%
as of March 31, 2026
Industry median 10.44% (56 companies)
Return on Equity
1.10%
as of March 31, 2026
Industry median 10.16% (58 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.19)
  • No Return on equity is 15% or more (1.1%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (87.2% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
2.4%
Low 113.5100 · High 115.9000
1W return
0.6%
Low 112.2000 · High 117.7300
1M return
6.2%
Low 105.0000 · High 117.7300
52W return
-5.7%
Low 97.5900 · High 147.0000
Lifetime High ₹141.3800 (Jan. 29, 2026)
Lifetime Low ₹5.0000 (Aug. 16, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
114.7
10D
114.3
20D
113.8
50D
114.8
100D
116.0
200D
116.5

Delivery and volume

Day avg. delivery
80.8%
Week avg. delivery
81.3%
Month avg. delivery
81.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

115.10
Pivot
First resistance116.69
Second resistance117.49
Third resistance119.08
First support114.30
Second support112.71
Third support111.91
Day RSI55.2
Day MFI65.5
Day MACD0.23
Day MACD signal-0.21

Beta

1M1.16
3M0.64
1Y0.87
3Y0.85

Price change analysis

↑ 6.2%
Over 1 Month
LowHigh
105.00117.73
↓ -2.2%
Over 3 Months
LowHigh
105.00131.98
↑ 13.8%
Over 6 Months
LowHigh
100.01143.20
↓ -5.7%
Over 1 Year
LowHigh
97.59147.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 1448.6 (own history: 39.5–2455.5)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹17 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.3000

Ranks #38 of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter40.14%

Largest holders

NameCategoryShares %Shares
Sangeetha SPromoter34.9800%7274272
Kovai Purani Finance Private LimitedPublic7.9300%1649578
Vramath Investment Consultancy Private LimitedPublic4.8400%1006744
Vramath Financial Services Private LimitedPublic4.6700%971873
Rajiv ChoudharyPublic4.5300%942005

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 40.14% in Jun 2026 qtr

Historical fii holding

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 75 insider trades, 10 SAST, 3 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
8 Jul 2024 S Rajkumar Promoter Sell 0 ₹0
20 Jun 2024 S Rajkumar Promoter Sell 0 ₹0
12 Mar 2024 S Rajkumar Promoter Sell 0 ₹0
26 Dec 2023 S Rajkumar Promoter Pledge Revoke 0 ₹3.15 Cr
6 Dec 2023 S Rajkumar Promoter Sell 0 ₹0
20 Jun 2023 S Rajkumar Promoter Buy 0 ₹0
13 Jun 2023 S Rajkumar Promoter Buy 0 ₹0
18 Apr 2022 S Rajkumar Promoter Pledge 0 ₹3.15 Cr
1 Apr 2021 DR. K.S RAMALINGAM Director Buy 0 ₹0
9 Mar 2021 SANGEETHA SUNDARAMOORTHY Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 182 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
1 Sep 2025 . THOMAS SANTOSH Bulk Buy 124,682 123.9400 NSE
18 Mar 2025 . VRAMATH FINANCIAL SERVICES PVT LTD Bulk Buy 113,269 58.0700 NSE
13 Aug 2024 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 126,566 76.5700 NSE
13 Aug 2024 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 126,566 76.4600 NSE
13 Aug 2024 . VRAMATH FINANCIAL SERVICES PVT LTD Bulk Buy 201,590 74.1100 NSE
13 Aug 2024 . VRAMATH FINANCIAL SERVICES PVT LTD Bulk Sell 201,590 77.1100 NSE
12 Jul 2024 . VRAMATH FINANCIAL SERVICES PVT LTD Bulk Buy 131,328 65.2700 NSE
12 Jul 2024 . VRAMATH FINANCIAL SERVICES PVT LTD Bulk Sell 31,328 68.9400 NSE
11 Mar 2024 RAJEEV CHOUDHARY Bulk Buy 120,000 66.2000 NSE
6 Mar 2024 QE SECURITIES LLP Bulk Buy 134,621 69.4400 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
18 Sep 2023 Dividend - Re 0.50 Per Share 0.5000 18 Sep 2023
8 Sep 2022 Annual General Meeting/Dividend - Re 0.50 Per Sh 0.5000 —
8 Sep 2021 Annual General Meeting/Dividend - Rs 0.50 Per Share 0.5000 —
14 Sep 2018 Annual General Meeting/Dividend Re 0.5 Per Share 0.5000 —
2 Aug 2017 Annual General Meeting/Dividend - Re 0.50 Per Share 0.5000 —

Corporate Actions

Full history (18 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Lotus Eye Care Hospital Limited to Lotus Eye Hospital And Institute Limited
18 Sep 2023OTHERAnnual General Meeting
19 Nov 2020OTHER Annual General Meeting
16 Sep 2019OTHER Annual General Meeting
23 Aug 2016OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
26 May 2026 Financial Results Yes
17 Mar 2026 Voluntary Delisting —
11 Feb 2026 Financial Results Yes
12 Nov 2025 Financial Results Yes

Corporate Announcements

All 423 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST Lotus Eye Hospital And Institute Ltd - 532998 - Closure of Trading Window
25 Sep 2026 Trading Window Lotus Eye Hospital and Institute Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
24 Sep 2026 Shareholders meeting LOTUSEYE: Lotus Eye Hospital and Institute Limited has submitted Voting Results and Scrutinizers Report for the Annual General Meeting held on September 23, 2026.
23 Sep 2026 Shareholders meeting LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 23, 2026
1 Sep 2026 Copy of Newspaper Publication LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Publication regarding 29th Annual General Meeting and Annual Report for the financial year 2025-26.
1 Sep 2026 Shareholders meeting LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about 29th Annual General Meeting scheduled to be held on September 23, 2026.
27 Aug 2026 Press Release LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding a press release dated August 27, 2026, titled "Launch of 'Lotus Optique', a new optical store.".
11 Aug 2026 Copy of Newspaper Publication LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Advertisements published for Standalone Unaudited Financial Results for the quarter ended June 30, 2026
10 Aug 2026 Outcome of Board Meeting LOTUSEYE: Lotus Eye Hospital and Institute Limited has submitted to the Exchange, the Standalone Unaudited Financial Results for the period ended June 30, 2026.
6 Jul 2026 Certificate under SEBI (Depositories and Participants) Regulations, 2018 LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.19)
  • Strong revenue growth YoY (26.2%)

Weaknesses

  • Low Return on Equity (1.1%)
  • Thin net profit margin (4.0%)
  • Declining profit YoY (-12.5%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (1448.6) -- priced for continued strong execution
  • Weak interest coverage (1.2x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Lotus Eye Hospital and Institute Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.